{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:22Z","timestamp":1794047482057,"version":"4.8.0"},"reference-count":37,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>We evaluated response to venetoclax\/hypomethylating agents (HMA) in 46 patients with acute myeloid leukemia (AML) characterized by extramedullary disease. The median age of these patients was 65 years (range, 19-81). The patients had a median of two sites of extramedullary disease (range, 1-5) and 35 (76%) had concurrent bone marrow involvement. Twenty (43%) patients had high-risk genetic features according to the European LeukemiaNet 2022 classification. Twenty-nine (63%) had relapsed or were refractory after intensive chemotherapy, including 13 (28%) who had undergone prior allogeneic hematopoietic cell transplantation. Patients received a median of two cycles of venetoclax\/HMA (range, 1-31). Twenty (43%) patients achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi) after venetoclax\/HMA and five (11%) achieved a partial remission (PR). Six patients were subsequently consolidated with allogeneic hematopoietic cell transplantation (CR\/CRi, N=4; PR, N=2). The median follow-up was 49.1 months (95% confidence interval [95% CI]: 26.1 months - not reached) and the median overall survival was 6.4 months (95% CI: 5.1-11 months). One-year and 2-year overall survival rates were 29.3% (95% CI: 18.6-46.2%) and 12.3% (95% CI: 5.5-27.6%), respectively. Age, with a cutoff of 60 years, did not have an impact on overall survival (P=0.90). Relapse occurred in 12 of 20 (60%) patients who achieved CR\/CRi after venetoclax\/ HMA treatment. Of those, all except one succumbed to their disease. Six (30%) patients were in CR\/CRi at last follow-up and two (10%) died in CR. In our cohort of patients with AML with extramedullary disease with high-risk features, treatment with venetoclax\/HMA resulted in an encouraging overall response rate of 54% with a CR\/CRi rate of 43.5%. However, venetoclax\/ HMA alone may not be effective in maintaining disease control.<\/jats:p>","DOI":"10.3324\/haematol.2024.285985","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T11:08:33Z","timestamp":1727953713000},"page":"378-384","source":"Crossref","is-referenced-by-count":3,"title":["Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax\/hypomethylating agents"],"prefix":"10.3324","volume":"110","author":[{"given":"Sabine","family":"Kayser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Sanber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Kelkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cerrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Tuyet","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Stidsholt","family":"Roug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Saraceni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selene","family":"Guerzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Lessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Borlenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Levis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Schlenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"71996","doi-asserted-by":"crossref","unstructured":"Muss HB, Moloney WC. Chloroma and other myeloblastic tumors. Blood. 1973; 42(5):721-728.","DOI":"10.1182\/blood.V42.5.721.721"},{"key":"71997","doi-asserted-by":"crossref","unstructured":"Chang H, Brandwein J, Yi QL, Chun K, Patterson B, Brien B. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leuk Res. 2004; 28(10):1007-1011.","DOI":"10.1016\/j.leukres.2004.01.006"},{"key":"71998","doi-asserted-by":"crossref","unstructured":"Tallman MS, Kim HT, Paietta E. Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group. J Clin Oncol. 2004; 22(7):1276-1286.","DOI":"10.1200\/JCO.2004.08.060"},{"key":"71999","doi-asserted-by":"crossref","unstructured":"Tallman MS, Hakimian D, Shaw JM. Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin Oncol. 1993; 11(4):690-697.","DOI":"10.1200\/JCO.1993.11.4.690"},{"key":"72000","doi-asserted-by":"crossref","unstructured":"Byrd JC, Weiss RB, Arthur DC. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol. 1997; 15(2):466-475.","DOI":"10.1200\/JCO.1997.15.2.466"},{"key":"72001","doi-asserted-by":"crossref","unstructured":"Kapur R, Steinberg A, Moussly A, Trias JA, Quintas J. Widespread myeloid sarcoma with KMT2A rearrangement involving the testis, oral cavity, heart, kidney and gallbladder without bone marrow involvement. Leuk Res Rep. 2022; 18:100349.","DOI":"10.1016\/j.lrr.2022.100349"},{"key":"72002","doi-asserted-by":"crossref","unstructured":"Kobayashi R, Tawa A, Hanada R. Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia. Pediatr Blood Cancer. 2007; 48(4):393-398.","DOI":"10.1002\/pbc.20824"},{"key":"72003","doi-asserted-by":"crossref","unstructured":"Oestgaard LSG, Sengeloev H, Holm MS. Extramedullary leukemia and myeloid sarcoma in AML: results from a population-based registry study of 2261 patients. Blood. 2011; 118(21):2003.","DOI":"10.1182\/blood.V118.21.2003.2003"},{"key":"72004","doi-asserted-by":"crossref","unstructured":"Tsimberidou AM, Kantarjian HM, Wen S. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer. 2008; 113(6):1370-1378.","DOI":"10.1002\/cncr.23691"},{"key":"72005","doi-asserted-by":"crossref","unstructured":"Ganzel C, Manola J, Douer D. Extramedullary disease in adult acute myeloid leukemia is common but lacks independent significance: analysis of patients in ECOG-ACRIN cancer research group trials, 1980-2008. J Clin Oncol. 2016; 34(29):3544-3553.","DOI":"10.1200\/JCO.2016.67.5892"},{"key":"72006","doi-asserted-by":"crossref","unstructured":"Rozovski U, Ohanian M, Ravandi F. Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. Leuk Lymphoma. 2015; 56(5):1392-1397.","DOI":"10.3109\/10428194.2014.953148"},{"key":"72007","doi-asserted-by":"crossref","unstructured":"Cheng CL, Li CC, Hou HA. Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults. BMC Cancer. 2015; 15:344.","DOI":"10.1186\/s12885-015-1376-9"},{"key":"72008","doi-asserted-by":"crossref","unstructured":"Goulart H, Sastow D, Moshier E, Martin L, Mascarenhas J, Tremblay D. Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement. Leuk Res. 2024; 137:107452.","DOI":"10.1016\/j.leukres.2024.107452"},{"key":"72009","doi-asserted-by":"crossref","unstructured":"Tallman MS, Wang ES, Altman JK. Acute myeloid leukemia, version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2019; 17(6):721-749.","DOI":"10.6004\/jnccn.2019.0028"},{"key":"72010","doi-asserted-by":"crossref","unstructured":"Loscocco GG, Vannucchi AM. Myeloid sarcoma: more and less than a distinct entity. Ann Hematol. 2023; 102(8):1973-1984.","DOI":"10.1007\/s00277-023-05288-1"},{"key":"72011","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Jonas BA, Pullarkat V. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617-629.","DOI":"10.1056\/NEJMoa2012971"},{"key":"72012","doi-asserted-by":"crossref","unstructured":"Wei AH, Montesinos P, Ivanov V. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020; 135(24):2137-2145.","DOI":"10.1182\/blood.2020004856"},{"key":"72013","doi-asserted-by":"crossref","unstructured":"Kayser S, Levis MJ. The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica. 2023; 108(2):308-320.","DOI":"10.3324\/haematol.2022.280801"},{"key":"72014","doi-asserted-by":"crossref","unstructured":"Bennett JM, Catovsky D, Daniel MT. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103(4):620-625.","DOI":"10.7326\/0003-4819-103-4-620"},{"key":"72015","unstructured":"Mitelman F. ISCN 1995: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland. 1995."},{"key":"72016","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.","DOI":"10.1182\/blood-2016-08-733196"},{"key":"72017","doi-asserted-by":"crossref","unstructured":"Yokota S, Kiyoi H, Nakao M. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 1997; 11(10):1605-1609.","DOI":"10.1038\/sj.leu.2400812"},{"key":"72018","doi-asserted-by":"crossref","unstructured":"Thiede C, Steudel C, Mohr B. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002; 99(12):4326-4335.","DOI":"10.1182\/blood.V99.12.4326"},{"key":"72019","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"72020","doi-asserted-by":"crossref","unstructured":"Cheson BD, Bennett JM, Kopecky KJ. Revised recommendations of the International orking Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-4649.","DOI":"10.1200\/JCO.2003.04.036"},{"key":"72021","doi-asserted-by":"crossref","unstructured":"Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996; 17(4):343-346.","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"72022","doi-asserted-by":"crossref","unstructured":"Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53(282):457-481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"72023","doi-asserted-by":"crossref","unstructured":"Mantel N, Byar D. Evaluation of response-time data involving transient states: an illustration using heart transplant data. J Am Stat Assoc. 1974; 69(345):81-86.","DOI":"10.1080\/01621459.1974.10480131"},{"key":"72024","unstructured":"R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria,. 2014. Publisher Full Text|"},{"key":"72025","doi-asserted-by":"crossref","unstructured":"Del Principe MI, Buccisano F, Soddu S. Involvement of central nervous system in adult patients with acute myeloid leukemia: incidence and impact on outcome. Semin Hematol. 2018; 55(4):209-214.","DOI":"10.1053\/j.seminhematol.2018.02.006"},{"key":"72026","doi-asserted-by":"crossref","unstructured":"Rozovski U, Ohanian M, Ravandi F. Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. Leuk Lymphoma. 2015; 56(5):1392-1397.","DOI":"10.3109\/10428194.2014.953148"},{"key":"72027","doi-asserted-by":"crossref","unstructured":"Byrd JC, Edenfield WJ, Shields DJ, Dawson NA. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol. 1995; 13(7):1800-1816.","DOI":"10.1200\/JCO.1995.13.7.1800"},{"key":"72028","doi-asserted-by":"crossref","unstructured":"Bae S, Sa S, Park S, Cho BS, Kim HJ. Limited efficacy of venetoclax combination regimens in acute myeloid leukemia with extramedullary relapse. Acta Haematol. 2024; 147(3):352-359.","DOI":"10.1159\/000534026"},{"key":"72029","doi-asserted-by":"crossref","unstructured":"Sanber K, Ye K, Tsai HL. Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease. Leuk Lymphoma. 2023; 64(4):846-855.","DOI":"10.1080\/10428194.2023.2173523"},{"key":"72030","doi-asserted-by":"crossref","unstructured":"Gangat N, Guglielmelli P, Szuber N. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases. Am J Hematol. 2021; 96(7):781-789.","DOI":"10.1002\/ajh.26186"},{"key":"72031","doi-asserted-by":"crossref","unstructured":"King AC, Weis TM, Derkach A. Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. Am J Hematol. 2022; 97(1):E7-E10.","DOI":"10.1002\/ajh.26381"},{"key":"72032","doi-asserted-by":"crossref","unstructured":"Tremblay D, Feld J, Dougherty M. Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm. Leuk Res. 2020; 98:106456.","DOI":"10.1016\/j.leukres.2020.106456"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285985\/77604","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285985\/78032","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11775\/77604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:22Z","timestamp":1794046042000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285985","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,3]]}}}